Financials data is unavailable for this security.
Cash flow in USDView more
In 2023, cash reserves at Iovance Biotherapeutics Inc fell by 56.84m. Cash Flow from Financing totalled 462.96m or 38,936.84% of revenues. In addition the company used 361.82m for operations while cash used for investing totalled 155.24m.
Cash flow per share | -1.36 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 2.54 |
---|---|
Tangible book value per share | 1.53 |
More ▼
Balance sheet in USDView more
Current ratio | 4.22 |
---|---|
Quick ratio | 3.90 |
Total debt/total equity | 0.0013 |
---|---|
Total debt/total capital | 0.0013 |
More ▼